Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

26.81 +0.78 (+3.00%)
Streaming Delayed Price Updated: 11:09 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Report Second Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
8 Analysts Have This to Say About Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings for Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Analyst Expectations for Arcutis Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
Why Shares of Arcutis Biotherapeutics Jumped This Week ↗
The stock got a push when a British medical journal posted trials information on the company's lead product. 
Via The Motley Fool
News headline image
The Latest Analyst Ratings for Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Arcutis Biotherapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Where Arcutis Biotherapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Arcutis Biotherapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
7 Short-Interest Stocks to Target for Explosive Gains ↗
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday ↗
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Report First Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months ↗
 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.